

United States Pulmonary Arterial Hypertension (PAH) Therapeutics Market Report 2016

<https://marketpublishers.com/r/UFD4E1462FFEN.html>

Date: November 2016

Pages: 114

Price: US\$ 3,800.00 (Single User License)

ID: UFD4E1462FFEN

Abstracts

Notes:

Sales, means the sales volume of Pulmonary Arterial Hypertension (PAH) Therapeutics

Revenue, means the sales value of Pulmonary Arterial Hypertension (PAH) Therapeutics

This report studies sales (consumption) of Pulmonary Arterial Hypertension (PAH) Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

Actelion Pharmaceuticals Ltd. (Switzerland)

Arena Pharmaceuticals, Inc. (US)

Bayer HealthCare Pharmaceuticals (Germany)

Cipla Limited (India)

Daiichi Sankyo Co., Ltd. (Japan)

Eli Lilly and Company (US)

Gilead Sciences, Inc. (US)

GlaxoSmithKline Plc (UK)

Nippon Shinyaku Co., Ltd. (Japan)

Pfizer, Inc. (US)

Sanofi S.A (France)

The Novartis Group (Switzerland)

United Therapeutics Corp. (US)

YM BioSciences, Inc. (Canada)

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

Type I

Type II

Type III

Split by applications, this report focuses on sales, market share and growth rate of Pulmonary Arterial Hypertension (PAH) Therapeutics in each application, can be divided into

Application 1

Application 2

Application 3

Contents

United States Pulmonary Arterial Hypertension (PAH) Therapeutics Market Report 2016

1 PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS OVERVIEW

1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH)

Therapeutics

1.2 Classification of Pulmonary Arterial Hypertension (PAH) Therapeutics

1.2.1 Type I

1.2.2 Type II

1.2.3 Type III

1.3 Application of Pulmonary Arterial Hypertension (PAH) Therapeutics

1.3.1 Application

1.3.2 Application

1.3.3 Application

1.4 United States Market Size Sales (Value) and Revenue (Volume) of Pulmonary Arterial Hypertension (PAH) Therapeutics (2011-2021)

1.4.1 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2021)

1.4.2 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)

2 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS COMPETITION BY MANUFACTURERS

2.1 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share of Key Manufacturers (2015 and 2016)

2.2 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Share by Manufactures (2015 and 2016)

2.3 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Average Price by Manufactures (2015 and 2016)

2.4 Pulmonary Arterial Hypertension (PAH) Therapeutics Market Competitive Situation and Trends

2.4.1 Pulmonary Arterial Hypertension (PAH) Therapeutics Market Concentration Rate

2.4.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share of Top 3 and Top 5 Manufacturers

2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Type (2011-2016)

3.2 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Market Share by Type (2011-2016)

3.3 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Price by Type (2011-2016)

3.4 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Type (2011-2016)

4 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Market Share by Application (2011-2016)

4.2 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Application (2011-2016)

4.3 Market Drivers and Opportunities

5 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS MANUFACTURERS PROFILES/ANALYSIS

5.1 Actelion Pharmaceuticals Ltd. (Switzerland)

5.1.1 Company Basic Information, Manufacturing Base and Competitors

5.1.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.1.2.1 Type I

5.1.2.2 Type II

5.1.3 Actelion Pharmaceuticals Ltd. (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.1.4 Main Business/Business Overview

5.2 Arena Pharmaceuticals, Inc. (US)

5.2.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.2.2.1 Type I

5.2.2.2 Type II

5.2.3 Arena Pharmaceuticals, Inc. (US) Pulmonary Arterial Hypertension (PAH)

Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.2.4 Main Business/Business Overview

5.3 Bayer HealthCare Pharmaceuticals (Germany)

5.3.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.3.2.1 Type I

5.3.2.2 Type II

5.3.3 Bayer HealthCare Pharmaceuticals (Germany) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.3.4 Main Business/Business Overview

5.4 Cipla Limited (India)

5.4.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.4.2.1 Type I

5.4.2.2 Type II

5.4.3 Cipla Limited (India) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.4.4 Main Business/Business Overview

5.5 Daiichi Sankyo Co., Ltd. (Japan)

5.5.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.5.2.1 Type I

5.5.2.2 Type II

5.5.3 Daiichi Sankyo Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.5.4 Main Business/Business Overview

5.6 Eli Lilly and Company (US)

5.6.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.6.2.1 Type I

5.6.2.2 Type II

5.6.3 Eli Lilly and Company (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.6.4 Main Business/Business Overview

5.7 Gilead Sciences, Inc. (US)

5.7.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.7.2.1 Type I

5.7.2.2 Type II

5.7.3 Gilead Sciences, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.7.4 Main Business/Business Overview

5.8 GlaxoSmithKline Plc (UK)

5.8.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.8.2.1 Type I

5.8.2.2 Type II

5.8.3 GlaxoSmithKline Plc (UK) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.8.4 Main Business/Business Overview

5.9 Nippon Shinyaku Co., Ltd. (Japan)

5.9.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.9.2.1 Type I

5.9.2.2 Type II

5.9.3 Nippon Shinyaku Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.9.4 Main Business/Business Overview

5.10 Pfizer, Inc. (US)

5.10.2 Pulmonary Arterial Hypertension (PAH) Therapeutics Product Type, Application and Specification

5.10.2.1 Type I

5.10.2.2 Type II

5.10.3 Pfizer, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

5.10.4 Main Business/Business Overview

5.11 Sanofi S.A (France)

5.12 The Novartis Group (Switzerland)

5.13 United Therapeutics Corp. (US)

5.14 YM BioSciences, Inc. (Canada)

6 PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS MANUFACTURING COST ANALYSIS

6.1 Pulmonary Arterial Hypertension (PAH) Therapeutics Key Raw Materials Analysis

6.1.1 Key Raw Materials

6.1.2 Price Trend of Key Raw Materials

6.1.3 Key Suppliers of Raw Materials

- 6.1.4 Market Concentration Rate of Raw Materials
- 6.2 Proportion of Manufacturing Cost Structure
 - 6.2.1 Raw Materials
 - 6.2.2 Labor Cost
 - 6.2.3 Manufacturing Expenses
- 6.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Therapeutics

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 7.1 Pulmonary Arterial Hypertension (PAH) Therapeutics Industrial Chain Analysis
- 7.2 Upstream Raw Materials Sourcing
- 7.3 Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Therapeutics Major Manufacturers in 2015
- 7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 8.1 Marketing Channel
 - 8.1.1 Direct Marketing
 - 8.1.2 Indirect Marketing
 - 8.1.3 Marketing Channel Development Trend
- 8.2 Market Positioning
 - 8.2.1 Pricing Strategy
 - 8.2.2 Brand Strategy
 - 8.2.3 Target Client
- 8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

- 9.1 Technology Progress/Risk
 - 9.1.1 Substitutes Threat
 - 9.1.2 Technology Progress in Related Industry
- 9.2 Consumer Needs/Customer Preference Change
- 9.3 Economic/Political Environmental Change

10 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPEUTICS MARKET FORECAST (2016-2021)

10.1 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue Forecast (2016-2021)

10.2 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Type (2016-2021)

10.3 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Forecast by Application (2016-2021)

10.4 Pulmonary Arterial Hypertension (PAH) Therapeutics Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Author List

Disclosure Section

Research Methodology

Data Source

Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Pulmonary Arterial Hypertension (PAH) Therapeutics

Table Classification of Pulmonary Arterial Hypertension (PAH) Therapeutics

Figure United States Sales Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Type in 2015

Table Application of Pulmonary Arterial Hypertension (PAH) Therapeutics

Figure United States Sales Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Application in 2015

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales and Growth Rate (2011-2021)

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate (2011-2021)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales of Key Manufacturers (2015 and 2016)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Manufacturers (2015 and 2016)

Figure 2015 Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Manufacturers

Figure 2016 Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Manufacturers

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue by Manufacturers (2015 and 2016)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Manufacturers (2015 and 2016)

Table 2015 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Manufacturers

Table 2016 United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Manufacturers

Table United States Market Pulmonary Arterial Hypertension (PAH) Therapeutics Average Price of Key Manufacturers (2015 and 2016)

Figure United States Market Pulmonary Arterial Hypertension (PAH) Therapeutics Average Price of Key Manufacturers in 2015

Figure Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share of Top 3 Manufacturers

Figure Pulmonary Arterial Hypertension (PAH) Therapeutics Market Share of Top 5 Manufacturers

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Type (2011-2016)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Share by Type (2011-2016)

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share by Type in 2015

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Market Share by Type (2011-2016)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue Share by Type (2011-2016)

Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Therapeutics by Type (2011-2016)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Price by Type (2011-2016)

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Type (2011-2016)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales by Application (2011-2016)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share by Application (2011-2016)

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share by Application in 2015

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Application (2011-2016)

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Growth Rate by Application (2011-2016)

Table Actelion Pharmaceuticals Ltd. (Switzerland) Basic Information List

Table Actelion Pharmaceuticals Ltd. (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Figure Actelion Pharmaceuticals Ltd. (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Arena Pharmaceuticals, Inc. (US) Basic Information List

Table Arena Pharmaceuticals, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Arena Pharmaceuticals, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Bayer HealthCare Pharmaceuticals (Germany) Basic Information List

Table Bayer HealthCare Pharmaceuticals (Germany) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Bayer HealthCare Pharmaceuticals (Germany) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Cipla Limited (India) Basic Information List

Table Cipla Limited (India) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Cipla Limited (India) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Daiichi Sankyo Co., Ltd. (Japan) Basic Information List

Table Daiichi Sankyo Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Daiichi Sankyo Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Eli Lilly and Company (US) Basic Information List

Table Eli Lilly and Company (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Eli Lilly and Company (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Gilead Sciences, Inc. (US) Basic Information List

Table Gilead Sciences, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Gilead Sciences, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table GlaxoSmithKline Plc (UK) Basic Information List

Table GlaxoSmithKline Plc (UK) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table GlaxoSmithKline Plc (UK) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Nippon Shinyaku Co., Ltd. (Japan) Basic Information List

Table Nippon Shinyaku Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Nippon Shinyaku Co., Ltd. (Japan) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Pfizer, Inc. (US) Basic Information List

Table Pfizer, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table Pfizer, Inc. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Sanofi S.A (France) Basic Information List

Table Sanofi S.A (France) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales,

Revenue, Price and Gross Margin (2011-2016)

Table Sanofi S.A (France) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table The Novartis Group (Switzerland) Basic Information List

Table The Novartis Group (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table The Novartis Group (Switzerland) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table United Therapeutics Corp. (US) Basic Information List

Table United Therapeutics Corp. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table United Therapeutics Corp. (US) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table YM BioSciences, Inc. (Canada) Basic Information List

Table YM BioSciences, Inc. (Canada) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)

Table YM BioSciences, Inc. (Canada) Pulmonary Arterial Hypertension (PAH) Therapeutics Sales Market Share (2011-2016)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Therapeutics

Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Therapeutics

Figure Pulmonary Arterial Hypertension (PAH) Therapeutics Industrial Chain Analysis

Table Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Therapeutics Major Manufacturers in 2015

Table Major Buyers of Pulmonary Arterial Hypertension (PAH) Therapeutics

Table Distributors/Traders List

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Production and Growth Rate Forecast (2016-2021)

Figure United States Pulmonary Arterial Hypertension (PAH) Therapeutics Revenue and Growth Rate Forecast (2016-2021)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Production Forecast by Type (2016-2021)

Table United States Pulmonary Arterial Hypertension (PAH) Therapeutics Consumption Forecast by Application (2016-2021)

I would like to order

Product name: United States Pulmonary Arterial Hypertension (PAH) Therapeutics Market Report 2016

Product link: <https://marketpublishers.com/r/UFD4E1462FFEN.html>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UFD4E1462FFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970